Alivus Life Sciences Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 26.1%
- Latest quarter profit grew 31.7% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.90x)
- Company has a consistent dividend-paying track record
CONS
- Promoter holding has decreased over last 2 years: -8.0pp
- Company has delivered a poor sales growth of 6.2% over past five years
- Company has delivered a poor profit growth of 9.9% over past five years
- Though reporting repeated profits, the company pays out little dividend (10.9%)
- Expensive relative to growth - PEG of 4.3
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1881.10 | 37.31 | 451338.90 | 0.85 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9570.55 | 86.86 | 254068.03 | 0.31 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4962.75 | 86.55 | 188767.06 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1150.00 | 25.42 | 114712.94 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1383.95 | 33.17 | 111803.57 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1945.50 | 96.14 | 105117.74 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1686.00 | 26.13 | 97008.71 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2112.00 | 17.47 | 96574.55 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1151.50 | 29.83 | 96113.39 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2305.85 | 46.63 | 95242.00 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2477.35 | 38.89 | 69916.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ALIVUS | 1373.50 | 27.96 | 16862.66 | 0.36 | 160.08 | 31.71 | 640.41 | 6.41 | 24.61 | 33.06 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | |
| 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 451 | |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 190 |
| OPM % | 33.39% | 28.06% | 30.12% | 26.36% | 27.10% | 26.51% | 29.65% | 30.55% | 28.63% | 30.47% | 34.37% | 31.13% | 29.64% |
| 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before Tax | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 25.58% | 25.29% | 26.09% | 24.48% | 25.80% | 25.22% | 26.03% | 25.84% | 25.43% | 25.33% | 24.26% | 24.62% | 24.57% |
| Net Profit | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.57 | 9.91 | 10.60 | 12.25 | 13.23 | 13.04 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 | |
| 0 | 639 | 1,065 | 1,294 | 1,507 | 1,519 | 1,609 | 1,704 | 1,755 | 1,776 | |
| Operating Profit | -0 | 247 | 472 | 591 | 616 | 642 | 674 | 683 | 797 | 815 |
| OPM % | -5.24% | 27.88% | 30.70% | 31.35% | 29.02% | 29.72% | 29.53% | 28.60% | 31.24% | 31.45% |
| 0 | 1 | 12 | 1 | 15 | 29 | 12 | 35 | 35 | 48 | |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| Profit before Tax | -0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | -3238.46% | 14.33% | 25.64% | 25.35% | 25.88% | 25.72% | 25.41% | 25.76% | 24.87% | 24.67% |
| Net Profit | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS | -433.82 | 1355.76 | 1597.37 | 32.61 | 35.63 | 38.11 | 38.43 | 39.63 | 45.99 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 61.45% | 55.10% | 58.55% | 12.62% | 10.87% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 6%
- 3 Years:
- 6%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 10%
- 3 Years:
- 7%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 47%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 22%
- 3 Years:
- 19%
- Last Year:
- 18%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| -1 | 86 | 400 | 751 | 2,026 | 2,107 | 2,297 | 2,783 | 3,300 | |
| 0 | 0 | 0 | 0 | 1 | 17 | 15 | 51 | 49 | |
| Trade Payables | 0 | 183 | 201 | 221 | 308 | 427 | 369 | 390 | 372 |
| 1 | 1,204 | 1,123 | 1,247 | 474 | 645 | 823 | 505 | 411 | |
| Total Liabilities | 0 | 1,475 | 1,726 | 2,221 | 2,834 | 3,220 | 3,528 | 3,754 | 4,157 |
| 0 | 456 | 546 | 573 | 590 | 781 | 805 | 955 | 1,038 | |
| Capital Work in Progress | 0 | 80 | 11 | 14 | 92 | 49 | 101 | 94 | 273 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 | |
| 0 | 401 | 413 | 513 | 516 | 604 | 667 | 674 | 692 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 765 | 970 | 1,073 | |
| Cash & Bank | 0 | 2 | 10 | 116 | 512 | 309 | 302 | 71 | 2 |
| 0 | 536 | 746 | 1,005 | 1,124 | 1,477 | 888 | 512 | 299 | |
| Total Assets | 0 | 1,475 | 1,726 | 2,221 | 2,834 | 3,220 | 3,528 | 3,754 | 4,157 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | 34 | 288 | 497 | 736 | 460 | 414 | 392 | 565 | |
| Cash from Investing | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Cash from Financing | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-08 - Alivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results.
2026-09-07 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet
2026-09-05 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet
2026-08-25 - Alivus Life Sciences Limited has informed the Exchange about Schedule of Investor/Analyst meeting
2026-08-18 - Alivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled "Alivus Life Sciences announces acquisition of majority stake in IQGenX.".
2026-08-18 - Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.
2026-08-13 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet of Investor/Analyst.
2026-08-13 - Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting information.
2026-08-11 - Alivus Life Sciences Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for FY 2025-26'.
News
Recent coverage and analyst commentary for ALIVUS
Loading news…
AI Stock Analyst
Alivus Life Sciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account